Vanguard Capital Management’s Rani Therapeutics RANI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.61M Buy
4,566,458
+3,473
+0.1% +$2.77K ﹤0.01% 3186
2026
Q2
$3.47M Sell
4,562,985
-59,582
-1% -$52.8K ﹤0.01% 3242
2026
Q1
$3.4M Buy
+4,622,567
New +$5.91M ﹤0.01% 3195

Other funds holding RANI

Vanguard Capital Management's RANI Position: Q3 2026 in Review

Vanguard Capital Management increased its Rani Therapeutics (RANI) stake by 0.08% in Q3 2026, buying an estimated $2.77K and bringing the position to 4,566,458 shares worth $3.61M. The position accounts for ﹤0.01% of the portfolio, ranked #3186.

Vanguard Capital Management first reported a position in RANI in Q1 2026 and has held it in 3 quarters since. 68 funds tracked by Wall St. Rank hold RANI as of Q3 2026.

  • Vanguard Capital Management held 4,566,458 shares of Rani Therapeutics worth $3.61M as of Q3 2026.
  • Vanguard Capital Management bought 3,473 Rani Therapeutics shares in Q3 2026, an estimated $2.77K.
  • Rani Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3186 holding.
  • Vanguard Capital Management first reported a position in Rani Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.